This trial is testing whether surgery and radiation therapy are more effective than just radiation therapy in treating patients with prostate cancer that has returned or spread.
- Prostate Cancer
- Metastatic Lymph Node Cancer
- Prostate Adenocarcinoma
- Prostate Specific Antigen Failure
- Bone Metastasis
1 Primary · 6 Secondary · Reporting Duration: Up to 3 years
3 Treatment Groups
Arm A (radiation therapy)
1 of 3
Arm C (salvage oligometastasectomy, radiation therapy)
1 of 3
Arm B (salvage oligometastasectomy)
1 of 3
40 Total Participants · 3 Treatment Groups
Primary Treatment: Metastasectomy · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · Male Participants · 9 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
To what degree is Metastasectomy a risk-free procedure?
"Our team at Power has assigned Metastasectomy a safety score of 2 because Phase 2 trials have only provided evidence confirming its security, not necessarily its efficacy." - Anonymous Online Contributor
How many volunteers are engaged in the experiment?
"Indeed, the information available on clinicaltrials.gov attests to this trial's ongoing recruitment efforts. It was first posted in September 2019 and last updated in January 2022; currently searching for 40 participants at a single site." - Anonymous Online Contributor
Are there still available spots in this trial for participants?
"As per information available on clinicaltrials.gov, this medical trial is currently accepting participants. It was initially posted in September 2019 and the latest update was made in April 2022." - Anonymous Online Contributor